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Background: Successful use of ablation for small hepatocellular carcinomas (HCC) has
led to interest in the role of ablation for colorectal liver metastases (CRLM). However,
there remains a lack of clarity about the use of ablation for colorectal liver metastases
(CRLM), specifically its efficacy compared with hepatic resection.
Methods: A systematic review of the literature on ablation or resection of colorectal
liver metastases was performed using MEDLINE, Cochrane Library, and Embase until
December 2018. The aim of this study was to summarize the evidence for ablation vs.
resection in the treatment of CRLM.
Results: This review identified 1,773 studies of which 18 were eligible for inclusion.
In the majority of the studies, overall survival (OS) and disease-free survival (DFS) were
significantly higher and local recurrence (LR) rates were significantly lower in the resection
groups. On subgroup analysis of solitary CRLM, resection was associated with improved
OS, DFS, and reduced LR. Three series assessed the outcome of resection vs. ablation
for technically resectable CRLM, and showed improved outcome in the resection group.
In fact, there were no studies showing a survival advantage of ablation compared to
resection in the treatment of CRLM.
Conclusions: Resection remains the “gold standard” in the treatment of CRLM and
should not be replaced by ablation at present. This review supports the use of ablation
only as an adjunct to resection and as a single treatment option when resection is not
safely possible.
Keywords: liver surgery, liver resection, colorectal liver metastases, radiofrequency ablation, systematic review
INTRODUCTION
Rationale
Colorectal cancer (CRC) is the third most common cancer worldwide (1). At the time of diagnosis,
30–50% of the patients already have (synchronous) or will develop (metachronous) colorectal
liver metastases (CRLM) in the further course of their disease (2). In metastatic CRC limited to
the liver without extrahepatic disease, resection of liver lesions remains the gold standard with
5 year survivals reported to be over 60% for selected patients (3, 4). The importance of surgery
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in the treatment of CRLM was recognized very early (5). Richard
Cattel performed the first resection of colorectal liver metastases
in 1940. However, it took several decades for the impact of liver
surgery on overall survival (OS) and disease free survival (DFS)
to be recognized (5).
One of the main goals of liver resection for CRLM is to
achieve a complete tumor removal with cancer free resection
margins (6, 7). With the introduction of better imaging, potent
chemotherapy and new surgical approaches, the boundaries of
treatment have been expanded in CRLM (6–8). Patients that
formerly seemed to be unresectable, nowadays have a chance
to undergo potentially curative resection. Even in patients with
extensive, bilobar CRLM and an expected marginal future liver
remnant (FLR), newly introducedmulti-stage resection strategies
offer a potential opportunity for cure by allowing time for
the liver to regenerate between the stages (6, 9, 10). Existing
approaches for multi- stage liver resections are the classical
two-stage hepatectomy (TSH) approach and the associating
liver partition and portal vein ligation for staged hepatectomy
(ALPPS) approach. In the “classical” two stage approach, portal
vein ligation (PVL) or portal vein embolization (PVE) is included
in the first stage to stimulate liver hypertrophy of the planned
FLR, followed by resection in the second step, most usually 4–
8 weeks later (after a confirmed appropriate volume increase of
the FLR) (11). The other two- stage approach, namely ALPPS,
was introduced more recently (10). Besides PVL/PVE, the first
step in ALPPS includes transection of the liver parenchyma (12).
ALPPS is able to accelerate liver growth facilitating the second
step within a shorter period of time, keeping the inter-stage
interval short and providing the potential benefit of a higher
resection rate compared to the classical two stage hepatectomy
approach in extensive colorectal liver disease (8, 13, 14). Despite
these developments, extending the limits of resectability, a
high percentage of patients with CRLM remain unresectable
either due to extensive liver disease or due to comorbidities
precluding resection (15). Therefore, a variety of local ablative
approaches have evolved to either complement resection or as
a single treatment modality for otherwise unresectable CRLM,
most commonly radiofrequency ablation (RFA) and microwave
ablation (MWA) (16, 17). These local ablative strategies have
shown to be safe and feasible in selected patient subpopulations
and the approach is well-accepted for patients who are not
candidates for resection (18). Over the last years the local ablative
strategies have shown promising results, with response rates up
to 95% and median survival rates up to 36 months (19).
Objectives
These encouraging data led to the demand of directly comparing
resection and ablation in CRLM to define the roles of the two
treatment modalities in the treatment algorithm of CRLM (20).
Research Question
Since the evidence on this topic is scarce, the aim of this study
was, based on a discussion at the EAHPBA 2019 in Amsterdam,
the Netherlands, to assess the evidence comparing resection and
RFA for the treatment of CRLM.
MATERIALS AND METHODS
Study Design
Since the majority of the available evidence involved RFA
(as opposed to other forms of thermal ablation) only, this
reviewed considered reports comparing RFA vs. resection in the
treatment of CRLM. The study followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
statement standards (21). Studies were identified by searching
the electronic databases EMBASE, MEDLINE, and Cochrane
Library. A professional experienced information specialist from
the Main Library of the University of Zurich performed
the literature search for published data, between September
and December 2018. A combination of subject headings and
keywords for liver resection, liver metastases, ablation therapy,
cryoablation, thermoablation electrocoagulation, radiofrequency
ablation, rectum tumor, colon tumor, and colorectal liver
metastases was used for the literature search.
Search Strategy
Keywords for the Search
exp Liver Neoplasms/sc or (exp neoplasm metastases/ or
exp neoplasm recurrence, local/) and ((hepatic or liver or
hepatocellular or hepato-cellular).mp.) or (hepatic or liver or
hepatocellular or hepato-cellular) adj3 (metasta∗ or secundar∗ or
spread or advanced)).ti,ab. or (hepatic or liver or hepatocellular
or hepato-cellular) adj3 ((neoplasm∗ or cancer∗ or carcinom∗
or tumo∗ or malign∗) and metasta∗).ti,ab. or (recurren∗ adj9
(liver or hepat∗) adj1 (neoplasm∗ or cancer∗ or carcinom∗ or
tumo∗ or metasta∗ or malign∗).ti,ab. exp colorectal neoplasms/
or (colorectal or colon∗ or rect∗) adj3 (neoplasm∗ or cancer∗
or carcinom∗ or adenocarcinom∗ or tumo∗ or malign∗).ti,ab.
exp Ablation Techniques/ or (ablation or cryotherapy or
thermoablati∗ or “thermo destruc∗” or “thermal destruc∗”
or “thermocoag∗” or “thermo coag∗” or “thermal coag∗” or
electrocoagulation or radiofrequ∗ or radio-frequ∗ or rfa or pei
or PAI).ti,ab. or (ablati∗ adj1 (therap∗ or method∗ or treatment∗
or procedure∗ or surgery or technique∗).ti,ab. or (injection adj5
(ethanol or “acetic acid”)).ti,ab.
Hepatectomy/or exp Liver Neoplasms/su or (liver or hepat∗
or surgical) adj3 (resect∗ or surgery).ti,ab. or (hepatectomy or
lobectomy).ti,ab. 1 and 2 and 3 and 4. The PRISMA flow chart
is shown in Figure 1. The last electronic literature search was
performed on 20 December 2018. PRISMA checklist is shown in
Supplementary Figure 1.
Data Extraction
Two reviewers independently reviewed the abstracts. Suitable
abstracts were identified and full text analysis was performed.
Discrepancies between reviewers were resolved after discussion
between them and the senior authors.
Data Selection
For final inclusion, studies had to compare the effects of ablation
(RFA) and hepatic resection (HR) in the treatment of CRLM.
Studies dealing with primary cancer or other ablation strategies
than RFA were excluded. Editorials, letters, abstracts, case reports
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FIGURE 1 | PRISMA flow chart of literature search.
were not included. All included studies had to be available
in English.
RESULTS
Study Selection and Characteristics
The systematic literature search identified 2,548 records.
Excluding duplicates, 1,773 publications were screened according
to title and abstract. Eight hundred and nine abstracts were
excluded due to language, topic, tumor entity, type ofmanuscript,
or because the full text was not available. In total, 964 publications
were eligible for full-text review. A further 946 were excluded
due to language, topic or tumor type. A total of 18 studies were
therefore included in the final analysis (Figure 1) (22–38).
Non-randomized Studies and Patients
Demographics
Eighteen non-randomized studies were identified. Seventeen
(94%) of the eighteen studies included were retrospective studies,
and only one was prospective. Among the 18 studies, seven (39%)
compared the outcomes following RFA vs. resection in solitary
CRLM (23, 24, 26, 28, 34, 37, 38). Three of the 18 studies (17%)
compared the two treatment modalities in potentially resectable
CRLM. In total, 2,667 patients were treated either with RFA (n
= 998, 37%) or hepatic resection (n = 1669, 63%). In 11.1% of
the studies included RFA was performed by surgeons. In 33.3%
of the cases RFA was performed by radiologists. In 55.6% of the
manuscripts included it was not clearly stated who performed
the intervention. Gender was reported for 2,420 patients, with
1,505 males (62.2%) and 915 (37.8%) females. The patient study
and detailed characteristics of the interventions are summarized
in Table 1. The study cohorts except one manuscript were not
matched. RFA was in the majority of the studies performed
when surgical resection was not an option due to insufficient
future liver remnant, unresectable disease or underlying patient
comorbidities precluding surgery. In one study (6%) RFA was the
first line treatment offered to all patients (35). Ko et al. performed
RFA in all patients declining HR as a first line treatment (38).
Wang et al. performed RFA if a complete necrosis based on tumor
size and position could be achieved, patients comorbidities that
precluded general anesthesia or surgery, and relying on patient
choice (40). In this analysis the cohorts were matched according
to the propensity score (40).
Overall Survival (OS)
Of the 18 studies included, eight (44%) studies showed a
significantly better overall survival in patients treated with
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TABLE 1 | Identified studies for the systematic review according to PRISMA guidelines.
References Study Modality Number of patients Gender m/f RFA via US/CT Open/percutaneous
Abdalla et al. (22) Retrospective RFA 57 Unclear US All RFA open during
Resection 190 Unclear Laparotomy
Agcaoglu et al. (25) Retrospective RFA 295 196/99 US All RFA done during
Resection 94 50/44 Laparoscopy
Aliyev et al. (26) Retrospective RFA 44 24/20 US All RFA done during
Resetion 60 34/26 Laparoscopy
Aloia et al. (23) Retrospective RFA 30 23/7 US Percutaneous/intraop
Resection 150 85/65
Gleisner et al. (27) Retrospective RFA 11 7/4 US All RFA open during
Resection 192 121/71 Laparotomy
Hur et al. (28) Retrospective RFA 25 15/10 US Intraop/percutaneous
Resection 42 27/15
Kim et al. (36) Retrospective RFA 177 121/56 US Intraop/percutaneous
Resetion 278 168/110
Kim et al. (29) Retrospective RFA 17 12/5 US Intraop/percutaneous
Resection 43 28/15
Ko et al. (38) Retrospective RFA 17 9/8 Modality unclear Intraop/percutaneous
Resection 12 9/3
Lee et al. (30) Retrospective RFA 37 26/11 US Percutaneous
Resection 116 76/40
Lee et al. (37) Retrospective RFA 28 23/5 US Percutaneous/intraop
Resection 25 14/11
McKay et al. (31) Retrospective RFA 43 25/18 US All RFA open during
Resection 58 29/29 Laparotomy
Oshowo et al. (24) Retrospective RFA 25 11/14 US/CT/MRI Percutaneous
Resection 20 10/10
Otto et al. (35) Prospective RFA 28 20/8 CT Percutaneous
Resection 82 49/33
Park et al. (32) Retrospective RFA 30 22/8 US/CT Percutaneous
Resection 59 41/18
Reuter et al. (33) Retrospective RFA 66 46/20 US Intraop
Resection 126 69/57
Wang et al. (39) Retrospective RFA 46 29/17 US Unclear
Resection 92 58/34
White et al. (34) Retrospective RFA 22 8/14 CT Unclear
Resection 30 20/10
RFA, Radiofrequency ablation; ns, not significant; DFS, disease free survival; OS, overall survival; y, year; PFS, Progression free survival; US, Ultrasound.
resection compared to RFA (22, 23, 25, 27, 28, 30–32; Table 2).
Ten studies (56%) did not show any difference in terms of overall
survival in favor of either treatment modality.
Disease Free Survival (DFS)/Progression
Free Survival (PFS)
Eight (44%) studies showed a significantly longer DFS for
patients undergoing hepatic resection compared to RFA. One
study (6%) showed a significant better progression free survival
(PFS) in the resection group (Table 2). Half of the studies showed
a significantly better DFS/PFS benefit for resection (Table 2). In
four (22%) of the 18 studies included, the DFS or the significance
between the two treatment groups are not reported. Almost a
third (28%) of the studies did not show any significance in favor
of one group (Table 2).
Local Recurrence Rate
In 10 (56%) of the 18 included studies the local recurrence rate
was significantly lower in patients treated with hepatic resection
compared to RFA. Three (16%) studies included did not report
their local recurrence rate following treatment with RFA or
hepatic resection. Five (28%) studies did not show any significant
differences in terms of local recurrence rate following the two
treatment modalities in favor of either group. Details are shown
in Table 2.
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TABLE 2 | DFS, OS, and Local recurrence rate of the studies included.
References Modality DFS in months Median OS in months 5y OS in % Local recurrence rate in %
Abdalla et al. (22) RFA 7 Significant 25 Significant 21 Significant 44 Significant
Resection 31 72 58 11
Agcaoglu et al. (25) RFA 8 Significant 31 Significant 17 Significant 69 ns
Resection 21 60 58 40
Aliyev et al. (26) RFA Not reported 22 ns 47 ns 18 Significant
Resection Not reported 25 57 4
Aloia et al. (23) RFA 0 Significant 47 Significant 27 Significant 37 Significant
Resection 50 126 71 5
Gleisner et al. (27) RFA 0 Significant 38.1 Significant 28.3 Significant 41.3 Significant
Resection 41.3 73.4 57.4 2
Hur et al. (28) RFA Not reported not reported 25.5 Significant 28 ns
Resection Not reported not reported 50.1 9.5
Kim et al. (36) RFA Not reported Significant not reported 14.3 ns Not reported
Resection not reported not reported 34.6 Not reported
Kim et al. (29) RFA 26.9 ns 30 ns 47.1 ns 76.5 ns
Resection 35 3 y DFS in % 57 53.3 3y OS 60.2
Ko et al. (38) RFA 17.6 ns na 37.8 ns Not reported
Resection 22.2 na 66.7 Not reported
Lee et al. (30) RFA 21.1 ns 40 ns 48.5 ns 29.7 Significant
Resection 23.7 44.7 65.7 6.9
Lee et al. (37) RFA 10 Significant 24 Significant Not reported 42.9 Significant
Resection 24 41 Not reported 8 Recurrence at margin
McKay et al. (31) RFA 15 ns 30 Significant 23 Significant 60 Significant
Resection 17 44 43 7
Oshowo et al. (24) RFA Not reported 34 ns 52.6 ns Not reported
Resection Not reported 41 55.5 3 y OS Not reported
Otto et al. (35) RFA Not reported 45 ns 60 ns 32 Significant
Resection Not reported 56 67 3 y OS 4
Park et al. (32) RFA Not reported Significant 36 Significant Not reported Significant 23.3 Significant
Resection Not reported 56 Not reported 1.7 Recurrence at margin
Reuter et al. (33) RFA Not reported 27 ns 21 ns 17 Significant
Resection Not reported 36.4 23 2
Wang et al. (39) RFA 14 Significant 74 ns 71.7 ns 15.2 ns
Resection 22 59 66.8 3 y OS 6.5
White et al. (34) RFA 17 Significant 31 Not clearly stated Not reported 55 Not reported
Resection 68 PFS 80 Not reported 12 Local disease progression
RFA, Radiofrequency ablation; ns, not significant; DFS, disease free survival; OS, overall survival; y, year; PFS, Progression free survival. The bold represent significant values.
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Subgroup Analysis
Solitary Colorectal Liver Metastases
There were seven studies which assessed outcomes in patients
with only a solitary liver metastases (23, 24, 26, 28, 34, 37, 38).
In total 630 patients were treated for solitary CRLM. Sixty eight
percent (n= 430) of patients were treated with resection and 32%
(n = 200) of patients were treated with ablation. Of the patients
treated with ablation, 116 (58%) were male and 84 (42%) female.
In the resection group 61% (n = 261) were male and 39% (n
= 169) female. Of the seven studies, only one (14.3%) showed
a significant advantage for resection in terms of 5 year DFS (50
vs. 0%; p = 0.001). White et al. demonstrated a significantly
longer PFS in patients undergoing resection (17 vs. 68 months,
p < 0.01). Two studies (28.6%) showed a significantly higher 5
year overall survival in the hepatic resection (HR) group (Aloia
et al. 27 vs. 71%; p < 0.001; Hur et al. 26 vs. 50%, p = 0.026)
(23, 28); Ko et al. showed a higher DFS and 5 year OS in the
HR group, but these differences were not significant (5 year DFS
18 vs. 22%; 5 year OS 38 vs. 67%) (38). Three studies (43%)
showed a significantly higher local recurrence rate in the RFA
group [Table 3; (23, 26, 37)]. Two additional studies also showed
a significant advantage for HR in terms of 5 year recurrence free
survival/PFS over RFA in the treatment of solitary colorectal liver
metastasis (28, 34, 37). In total, three studies (43%) showed a
significant advantage for HR compared to RFA on recurrence.
In a subgroup analysis, four out of these seven studies (57%)
provided enough data to assess the effects of RFA vs. HR for
solitary CRLM lesions ≤3 cm (23, 26, 28, 37, 38). A total of
255 patients were included, 125 (49%) underwent RFA and 130
(51%) patients underwent resection for solitary CRLM ≤ 3 cm
in size. Aloia et al. demonstrated a significantly higher 5 year
OS in the HR group (71 vs. 18%; p = 0.006; Table 4) and a
significantly lower local recurrence rate for the resection group
in this subgroup analysis (3 vs. 31%; p < 0.001) (23). Aliyev et al.
showed a significant advantage for resection compared to RFA in
terms of local recurrence (4 vs.18%; p= 0.012) (26, 34). Hur et al.
failed to show any significance for one of the treatment groups
when analyzing this particular subpopulation but did show a
significant higher survival rate (42 vs. 30%; p < 0.001) as well
as a significant longer LRFS (81 vs. 50 months; p = 0.013) in the
group of solitary CRLM > 3 cm in the resection group (28, 38).
These observations are further supported by the results from Ko
et al. (38). This group showed a significant lower 5 year OS as well
as a significantly lower 5 year DFS in the RFA group for patients
with solitary CRLM > 3 cm (5 year OS: 0 vs. 57%; p = 0.005 5
year DFS: 0 vs. 38.1%; p= 0.013).
RFA vs. Resection for resectable CRLM
In three of the 18 studies (16.7%) hepatic resection was compared
to RFA in potentially resectable CRLM (35, 38, 39). Two of the
studies were retrospective studies, with one prospective series. In
total 277 patients were included in this subgroup analysis. One
hundred and eighty-six patients (67%) underwent resection and
91 patients (33%) ablation. In the resection group 116 (63%)
were male and 70 (38%) female. Sixty four percent of patients
undergoing RFA were male and thirty six percent female. In the
study by Otto et al. RFA was considered as first line treatment. TA
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TABLE 4 | DFS, OS, and Local recurrence rate of the studies included with solitary CRLM ≤ 3cm.
References Modality DFS in months Median OS in months 5 y OS in % Local recurrence rate in %
Aliyev et al. (26) RFA Not reported 22 ns 47 ns 18 Significant
Resection Not reported 25 57 4
Aloia et al. (23) RFA Not reported Not reported 18 Significant 31 Significant
Resection Not reported Not reported 71 3
Hur et al. (28) RFA Not reported Not reported 55.4 ns 13.3 ns
Resection Not reported Not reported 56.1 4.3
Ko et al. (38) RFA Not reported Not reported 80 ns Not reported
Resection Not reported Not reported 49.5 Not reported
RFA, Radiofrequency ablation; ns, not significant; DFS, disease free survival; OS, overall survival; y, year. The bold represent significant values.
TABLE 5 | DFS, OS, and Local recurrence rate of the studies included with technically resectable CRLM.
References Modality DFS in months/5 y DFS in % Median OS in months 5 y OS in % Local recurrence rate in %
Ko et al. (38) RFA 17.6 ns Not reported 37.8 ns Not reported
Resection 22.2 Not reported 66.7 Not reported
Otto et al. (35) RFA not reported Not reported 67 ns 32 Significant
Resection not reported Not reported 60 3 y OS 4
Wang et al. (39) RFA 14 Significant 74 ns 71.7 ns 15.2 ns
Resection 22 59 66.8 3 y OS 6.5
RFA, Radiofrequency ablation; ns, not significant; DFS, disease free survival; OS, overall survival; y, year. The bold represent significant values.
Surgery was only performed in patients not suitable for RFA due
to number, size, or location of the metastases (35). Ko et al. only
performed RFA for CRLM when patients refused HR after being
informed about the two different treatment options, potential
complications and survival rates (38). In themanuscript byWang
et al. indications for RFA were as follows: complete necrosis
of the CRLM feasible, tumor size and position, comorbidities
precluding HR and patient choice (39).
Wang et al. and Otto et al. demonstrated a significant benefit
of resection in terms of local recurrence rate and time to local
recurrence compared to RFA in resectable CRLM (35, 39). The
local recurrence rate in in the resection group was 4 vs. 32%; p
< 0.001 in the RFA group (35). Wang et al. showed a significant
higher intrahepatic recurrence (37 vs. 12%; p= 0.001) in the RFA
group as well as a significant shorter time to recurrence in the
RFA group. Furthermore, they demonstrated a significant longer
survival in the resection group (22 vs. 14 months; p = 0.032;
Table 5) (39).
DISCUSSION
Hepatic resection is the treatment of choice for colorectal liver
metastases with 5 year OS approaching 60% (40, 41). Ablation
techniques have shown great promise in other disease types but
this does not mean that it should necessarily be applied to CRLM
(16, 42). Indeed, there remains a lack of clarity surrounding
the precise role of ablation compared to surgery for CRLM.
The American Society of Clinical Oncology (ASCO) guidelines
have highlighted the wide variation in overall survival and local
recurrence rates after ablation, and suggested that in the absence
of adequate data resection should remain the gold standard
treatment for resectable disease (43). Despite these concerns,
ablation may still have a role as an adjunct to resection. Patients
with small volume resectable metastases who are not sufficiently
fit to undergo liver resection can be considered for ablation as
should those with limited liver metastases who have insufficient
liver volume to undergo resection due to tumor position (24, 44).
Based on a discussion at the EAHPBA 2019 in Amsterdam, the
Netherlands, this systematic review was conducted to investigate
the contemporary evidence on ablation vs. resection for the
treatment of CRLM. So far there are no completed randomized
studies on this topic. The COLLISION trial is a randomized
controlled trial (RCT) comparing the efficacy of ablation and
resection in patients with at least one resectable and ablatable
CRLM with a maximal diameter of not more than 3 cm (45).
The protocol of this trial was published in 2018 but results are
still pending. Another ongoing RCT is the HELARC trial (Trial
ID NCT02886104). This study aims to compare surgical and
ablative strategies for the treatment of resectable synchronous
CRLM, with patients randomized to resection of the primary
tumor and resection or ablation of the liver metastases. The
study has an estimated completion date of 2026. A major UK
trial (LAVA) comparing the impact of resection and ablation on
disease free survival was aimed at patients mainly selected on
grounds of age and comorbidities and this recently closed due to
failure to recruit adequate patient numbers (46). One interesting,
unpublished study on this topic was presented at the EAHPBA
2019, by Engstrand et al. comparing the results of MWA and
resection in CRLM in a propensity score matched cohort with
promising results for MWA. Due to the limited evidence of
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published data on MWA and other interventional ablation
approaches in direct comparison with resection, RFA only was
chosen as the primary treatment of choice for comparison.
Summary of Main Findings
The present systematic review has shown a superior oncological
outcome following hepatic resection in comparison to RFA in
the treatment of CRLM. This systematic review has identified
a higher overall- and DFS in the HR group. RFA as a
single treatment was associated with a significantly higher local
recurrence. Even in a subgroup analysis of solitary CRLM and
solitary CRLM ≤ 3 cm HR showed oncological benefits in
DFS, OS and local recurrence rate. Within a subgroup analysis
comparing the effects of HR and RFA in technically resectable
CRLM, RFA produced inferior results.
Currently there are no results from RCTs available, directly
comparing the outcome of the two treatment modalities. There
are RCTs registered and protocols of these trials published and
their results are eagerly awaited. The failure of the UK LAVA trial
to recruit patients also highlights a potential equipoise amongst
surgeons regarding ablation vs. resection for resectable disease.
Although screening data has yet to be released for this study, it
may also be that patients were unwilling to be randomized to
ablation when surgery was an option. These data will be vital to
assess the feasibility of future trials.
RFA gained popularity as an interventional treatment option
for small hepatocellular carcinomas and on this background of
relative success RFA was postulated to be an effective alternative
also in CRLM, especially in the treatment of CRLM ≤ 3 cm (42,
47–50). However, in the absence of evidence, this was a dangerous
assumption. RFA is attractive in that it offers a minimally invasive
treatment alternative compared to HR, in conjunction with
lower post-interventional morbidity, lower complication rates
and shorter hospital stays compared to resection (22, 51–53). In
a review from Weng et al. overall complication rates following
RFA were significantly lower compared to hepatic resection (3.9
vs. 18.3%; p < 0.01). Van Amerong et al. support these results
in a meta-analysis published in 2017 (48). But these short-
term advantages do not translate into an oncological benefit.
This systematic review identified a higher OS in the resection
group compared to RFA. Eight (44%) of the 18 non-randomized
studies included in this analysis showed a significantly higher
OS following resection compared to RFA (22, 23, 25, 27,
28, 30–32). These results are similar to the results of other
meta-analyses (48, 49).
A potential explanation of the lack of OS benefit in five
of the studies could be that the investigators were comparing
the effects of the two treatment modalities for solitary CRLM
with better long-term outcomes (24, 26, 34, 37, 38). Indeed,
it could be argued that these data suggest that patients with
solitary metastases do equally well whether treated with ablation
or resection. This lack of difference in long term survival is made
even more intriguing by the results of Aliyev et al. who showed
that the local recurrence rate was significantly lower in patients
undergoing resection compared to ablation (26). It may therefore
be that local lesional recurrence in biologically good prognosis
patients has no impact on long term outcome. One additional
study also showed a significant advantage for HR in terms of local
recurrence free survival over RFA in the treatment of solitary
CRLM (34, 37). White et al. showed a lower disease progression
rate in the HR group (12 vs. 55%) that was not significant in
their analysis (34). Ko et al. showed a trend toward an improved
DFS and 5 year OS in the HR group, but these differences were
not significant, potentially triggered by a very limited number
of patients treated: 13 patients were assigned to the RFA group
and only five patients were included in the resection cohort (38).
When looking a little bit closer at the subgroup analysis of this
study, Ko et al. did show a significant advantage for resection
compared to RFA for bith DFS and 5 year OS for CRLM >
3 cm despite the very limited number of patients included in
this retrospective analysis. This finding is confirmed by other
studies and a tumor size > 3 cm was identified as an independent
negative predictor of outcome following RFA treatment (50).
Since Interventional treatment modalities have gained
popularity in the treatment of small tumors, RFA has been
postulated to be an effective treatment alternative, especially
in the treatment of CRLM ≤ 3 cm (42, 47–50). However, this
systematic review has shown in a subgroup analysis that HR is
still superior compared to RFA even for solitary CRLM ≤ 3 cm.
Aloia et al. also showed a significant advantage of HR compared
to RFA in this subgroup analysis in terms of LR rate (3 vs. 31%;
p < 0.001), 5 year LRFS (97 vs. 66%; p < 0.001), and 5 year OS
(72 vs. 18%; p = 0.006). Other studies have also demonstrated
a significant impact for HR on local control in this particular
subgroup (26, 34). One potential explanation of the missing
significance in LR rate, LR free survival, DFS 5 year and 5 year
overall survival in the HR group in the two other studies might
be that these studies were underpowered. Hur et al. included
38 patients in total (15 RFA and 23 HR) and 18 patients (13
RFA and 5 HR) were included in the study conducted by Ko
et al., respectively.
The difference in success rate for RFA for CRLM ≤ 3 cm
compared to the initial very promising treatment outcomes in
HCCmight be explained by a different biological behavior among
the two tumor entities. There is existing evidence that CRLM
are assessed as an independent risk factor, negatively influencing
the outcome following treatment. These findings of superiority
of HR in the treatment of CRLM, even in metastases ≤ 3 cm, are
supported by other studies as well, although some groups claim
that tumor size ≤ 3 cm and solitary metastases are prognostic
characteristics favorable to RFA (23, 48, 49).
Outcome is not only predicted by tumor size alone. The
approach of doing RFA itself has a significant impact on the
outcome. There is no consensus among experts which treatment
approach is most favorable: percutaneous, laparoscopic, or
open (laparotomy). Existing evidence suggests that open RFA
is associated with a significantly lower risk of LR compared
to percutaneous treatment (54–56). In a meta- analysis done
by Mulier et al., the percutaneous approach was identified
as an independent risk factor for poor outcome, independent
of tumor size. The potential short term advantages of the
percutaneous approach in terms of reduced invasiveness and
reducedmorbidity do not counterbalance the long-term effects of
inferior oncological outcome of this approach (54). When trying
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to assess the efficacy of laparoscopic RFA in comparison to open
RFA, results analyzing the outcome following these two treatment
modalities are much harder to find. In a manuscript published
by Mulier et al. the authors showed in their analysis that the
local recurrence rate following laparoscopic RFA was higher
compared to open RFA even for solitary metastases ≤3 cm (26.3
vs. 1.7%), respectively (57). However, this paper was published
in 2008. Improvements in imaging technologies may mean that
percutaneous ablation is now better able to accurately target and
destroy lesions. It will however, for the moment at least, rely on
operator dependability, whatever approach is used. Furthermore,
in 11% of the studies included, RFA was performed by surgeons
and in 33.3% by radiologists. In 55.6% it is not clearly stated who
performed the intervention. If the ablation procedure was not
performed by experienced radiologists this might potentially be
an additional factor explaining the superior outcome of surgery.
Recent studies have shown that intraoperative ultrasound is
associated with a higher accuracy in detecting CRLM compared
to the percutaneous treatment approach (58). The last argument
in favor for surgical RFA may be the better access. The surgical
approach, especially the open approach, gives the surgeon a
maximal freedom of placing the electrodes to treat the hepatic
disease whereas the percutaneous approach only offers a very
limited window of access (59, 60). This advantage of better
accessing the metastases in open RFA might also explain the
advantage in treatment efficacy compared to the laparoscopic
RFA approach.
The thermal ablation of colorectal metastases has been
clearly demonstrated to result in complete tumor destruction
in experimental models (61). Any difference in long- term
outcomes seen between ablation and resection must therefore
be explained by a different reason. This may be because occult
micrometastases are removed during hepatic resection surgery.
Although there is parity for OS, parenchymal sparing resection
is also associated with more local recurrence but not inferior in
OS due to more repeat resections in order to achieve the OS. This
may be the same for RFA (62). Lesional recurrence rates varied in
this review, andmay explain some of these long- term differences.
However, the EORTC 40004 study of RFA for irresectable CRLM
reported a lesional recurrence rate of 10% and so likely better
reflects contemporary management. More importantly, selection
for ablation is likely to represent a biologically worse cohort.
The failure of trials of ablation and resection to recruit suggest
that surgeons will try and offer surgical resection unless the
oncological prognosis is dismal, or patients are unfit for surgery.
It may therefore be selection for ablation itself reflects a worse
prognosis disease.
Ablation does offer some advantages, including lower post-
interventional morbidity, lower complication rates and shorter
hospital stays compared to resection but these advantages do not
compensate the inferior oncological outcome of RFA compared
to resection (22, 51–53). The mentioned short- term benefits of
RFA are more a justification for RFA as a treatment tool for
selected patient subgroups.
Thus, the available evidence shows that hepatic resection is
superior compared to RFA in the treatment of CRLM. In fact,
according to the available evidence and results, it is hard to justify
a RCT comparing RFA and HR in the treatment of resectable
CRLM even in solitary CRLM ≤3 cm since no study, especially
in this subgroup analysis could show an advantage for RFA.
Limitations
The clear strength of this systematic review is, that it provides
a comprehensive picture of all available evidence on RFA vs.
resection in the treatment of CRLM. As no RCTs are available on
this topic, the results of the included pro-/retrospective studies
have to be interpreted with caution, particularly as the majority
of the studies reviewed were retrospective. We found that the
groups compared in the different studies were inhomogeneous
in terms of patient characteristics. In the majority of the studies
included, patients assigned to RFA were not suitable for resection
due to medical fitness or resectability: patients eligible for RFA
seemed to be unresectable or too frail for resection, clearly
illustrating a selection bias representing a particular subgroup
of patients with poor prognosis in the RFA cohorts. Therefore,
the level of available evidence is low. In addition, the number
of patients included in several studies was limited. These studies
might be underpowered to detect any potential significance in
the outcomes.
Outlook
So far there is only limited evidence available in matched cohorts
comparing the outcome of these two treatment modalities.
The results of the HELARC trial as well as the study results
from Engstrand et al. in their propensity score matched cohort
are eagerly anticipated. Furthermore, with the introduction of
new technologies e.g., 3D navigation, multi needle ablation
and robotic approaches RFA has further improved. There
are promising results showing the efficacy of stereotactic
radiofrequency ablation (SRFA) even in the treatment of CRLM
up to 13 cm (63). But these new treatment approaches need
further testing in direct comparison with HR.
CONCLUSIONS
So far based on the available evidence resection remains
the gold standard in the treatment of CRLM, and cannot
be replaced by ablation at present. Although interventional
treatment approaches have gained popularity in other tumor
entities with promising results in certain subgroups, the available
data in this systematic review does not support the use of
RFA as a solitary curative treatment in CRLM. We recognize,
however, that in the treatment algorithm for CRLM ablation
has a role as an adjunct to surgery or as a single treatment
option in selected patient subgroups, especially in the treatment
of multimorbid patients.
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